After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pfizer expanded its cost-cutting ... program resulting from the Inflation Reduction Act will hurt sales by $1 billion, dampening growth by approximately 1.6% compared with 2024. Stripping out ...

Pfizer is raising the ... Of that total, $4.5 billion in net cost savings will be realized by the end of this year from an ongoing cost-realignment program, the company said in its first-quarter ...

(Reuters) -Pfizer said ... LEANING ON COST SAVINGS The company said it now expects about $7.7 billion in savings by the end of 2027 from its cost-cutting programs. That includes an additional ...

Pfizer adds the guidance does not include the potential impact of future changes in trade and tariff policies. Cost-Cutting Initiatives ... With the new target, total program savings are expected ...

Pfizer expects to incur about $1.7 billion as one-time costs for the first phase of the program. This also includes severance for an unspecified number of layoffs.

Photo: ABC News Pfizer on Tuesday reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker looks to turn around its business postpandemic.